Genetic variation

Pairwise Grants License to Proprietary Fulcrum™ Platform Tools to Solis Agrosciences for Custom Research and Product Development

Retrieved on: 
Donnerstag, Juni 6, 2024
Research, Organization, Genetic variation, IP, Genetics, Breeding, Coffee, Cherry, Environment, Food, Agriculture, Fulcrum, Partnership, CRISPR, SHARC

Through this license, Solis will be using Pairwise’s tools to drive innovative solutions to their clients’ global food and climate challenges.

Key Points: 
  • Through this license, Solis will be using Pairwise’s tools to drive innovative solutions to their clients’ global food and climate challenges.
  • Licensees of the Fulcrum Platform can receive access to Pairwise’s full suite of novel technologies and proprietary tools for applying CRISPR to research, develop, and commercialize products with differentiated plant genetics.
  • Once a product is ready to move from the R&D stage to commercialization, Solis’ clients can obtain a commercial license through Pairwise to take their products to market.
  • Learn more about licensing the Fulcrum Platform, as well as opportunities to develop new products through a collaborative partnership with Pairwise, here .

QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe

Retrieved on: 
Mittwoch, Juni 5, 2024
Nested polymerase chain reaction, PCR, Genome, Genetic, Research, Database, Genetic variation, Gene, Senior, MicroRNA, DNA, Health, QIAGEN, Medicine, Genetics, CNV, QGEN, Cancer

To keep pace and close the need gap, the new digital PCR Custom Assay Design Tool has been developed as an interface on the GeneGlobe platform.

Key Points: 
  • To keep pace and close the need gap, the new digital PCR Custom Assay Design Tool has been developed as an interface on the GeneGlobe platform.
  • “Our new digital PCR Custom Assay Design Tool in GeneGlobe provides researchers with an innovative and user-friendly tool to design customized assays for QIAcuity tailored to their specific needs, streamlining research and accelerating scientific discovery.”
    Additional enhancements of GeneGlobe have been launched recently or are currently in development.
  • QIAGEN is building a strong pipeline for customization and plans to expand the dPCR Custom Assay Design Tool capabilities to microbial and somatic mutation assays later in 2024.
  • When customers seek higher-order multiplexing or more complex assays, QIAGEN Genomic Services offers expert custom assay design support and assays are made available in GeneGlobe.

Global Microarray Industry Research 2023-2024 & 2033: Rising Numbers of Genomics Projects, Developing Focus on Automation and Artificial Intelligence Integration - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, Mai 16, 2024
Health, Genetics, Genomics, Gene expression profiling, Proteomics, DNA, Competitive landscape, Gene expression, Limited partnership, Prevalence, Conditional sentence, Region, Disease, Drug development, Microarray, Growth, Research, Cancer, Drug discovery, Medicine, Gene, Genetic variation, Merck, Software, Thermo Fisher Scientific, Illumina, Vaccine

This growth can be attributed to rising numbers of genomics projects fuelling the growth of microarray analysis market, use of microarray technology in drug screening, increasing adoption of microarray technology in cancer screening.

Key Points: 
  • This growth can be attributed to rising numbers of genomics projects fuelling the growth of microarray analysis market, use of microarray technology in drug screening, increasing adoption of microarray technology in cancer screening.
  • The global microarray analysis market has a significant impact on the biomedical industry, particularly in genomics and personalized medicine.
  • The global microarray analysis market continues to drive transformative advancements across industries, with far-reaching implications for human health, and environmental sustainability.
  • DNA microarrays are poised to maintain their dominance in the global microarray analysis market due to their critical role in genomics research.

Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 2, 2024
Technology, Biotechnology, Nanotechnology, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Other Science, Research, General Health, Genetics, Health Technology, Science, Data Management, Twist, Doctor of Philosophy, Nucleic acid thermodynamics, Net, Genomics, Investment, Exome, Capital, Sequence, PIN, Depreciation, Silicon, Genetic variation, Growth, Twist Bioscience, NGS, Development, Administration, SynBio, Tax, UHT, Adjustment, Telephone, GAAP, Element, Gene, Tobacco

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.
  • Shipped products to 2,253 customers in the second quarter of fiscal 2024, compared to approximately 2,100 customers in the second quarter of fiscal 2023.
  • Shipped approximately 193,000 genes during the second quarter of fiscal 2024, compared with approximately 152,000 genes during the second quarter of fiscal 2023.
  • For the third quarter of fiscal year 2024, Twist provided the following financial guidance:
    For the fourth quarter of fiscal year 2024, Twist provided the following financial guidance:
    1For in vitro diagnostic use.

Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing

Retrieved on: 
Donnerstag, April 11, 2024
B-ALL, OGM, RNA, WGS, Genetic variation, Doctor of Philosophy, Research, Leukemia, Bone marrow, Biomarker, Genomics, Whole genome sequencing, Cancer, SVS, SAN, Vaccine

The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.

Key Points: 
  • The study also used whole genome sequencing (WGS) for variant detection and evaluated the two approaches side-by-side and the potential benefit of integrating WGS and OGM to obtain a comprehensive analysis of genetic variation.
  • The study concluded that OGM together with WGS can potentially identify new therapeutic targets and improve personalized medicine in pediatric leukemia and other cancers by providing a more complete view of genome variation, including structural variation.
  • The study findings showed that, of the 3,075 total SVs detected in the B-ALL samples, 1,255 were uniquely detected by OGM.
  • The study also found that WGS detected 66 gene fusions, and that OGM was able to detect an additional 56 fusions that were missed by WGS.

Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder

Retrieved on: 
Donnerstag, April 18, 2024
Harvard University, University, Genetics, Post-traumatic stress disorder, Meta-analysis, Fear, Broad Institute, Eurosport 1, Neuroscience, Cognition, PTSD, Chairperson, Trauma, Hand, University of California, Genetic variation, Doctor of Philosophy, Research, URL, Life, Axon guidance, Native, Survivor, Therapy, SURFnet, Mental health, Psychiatric Genomics Consortium, DSM-IV codes, Psychiatric Genetics (journal), Nature Genetics, MIT, Genome, Diagnosis, Biology, NIMH, Synapse, Frequency response, Meat

NEW YORK, April 18, 2024 /PRNewswire/ -- The Global PTSD Genetics initiative founded in 2015 by Cohen Veterans Bioscience, the Stanley Center for Psychiatric Research at Broad Institute, and the Psychiatric Genomics Consortium today announces a pivotal milestone in the genetics of post-traumatic stress disorder (PTSD) has been achieved and published in Nature Genetics on April 18,2024.

Key Points: 
  • Convergent multiomic approaches identified 43 potential causal genes, including modulators of neurotransmitters, ion channels, axon guidance, and synapses.
  • Additional top genes influence stress, immune, fear, and threat-related processes, previously hypothesized to underlie PTSD neurobiology.
  • These findings strengthen the understanding of neurobiological systems relevant to PTSD pathophysiology, while also opening new areas for investigation.
  • Posttraumatic stress disorder (PTSD) is characterized by intrusive thoughts, hyperarousal, avoidance, and negative alterations in cognition and mood that can become persistent for some individuals after traumatic event exposure.

Computational Biology Pioneer Katie Pollard Elected as AAAS Fellow

Retrieved on: 
Donnerstag, April 18, 2024
Genomics, National academy, Chimpanzee, Physics, Sanders, AAAS, Mammal, HARS, Data science, Machine learning, MD, Computational biology, Doctor of Philosophy, Genetic variation, Artificial intelligence, History, William Ewart Gladstone, Disease, Engineering, Human, DNA, Gold, Senior, Chan Zuckerberg Biohub, Chemistry, Biostatistics, Gene expression, Genome, SAN, Management

SAN FRANCISCO, April 18, 2024 /PRNewswire/ -- The American Association for the Advancement of Science (AAAS), one of the world's largest general scientific societies, has elected Gladstone Senior Investigator Katie Pollard, PhD, into its new class of AAAS Fellows, a lifetime honor within the scientific community.

Key Points: 
  • SAN FRANCISCO, April 18, 2024 /PRNewswire/ -- The American Association for the Advancement of Science (AAAS), one of the world's largest general scientific societies, has elected Gladstone Senior Investigator Katie Pollard, PhD, into its new class of AAAS Fellows, a lifetime honor within the scientific community.
  • AAAS recognized Pollard for her "distinguished contributions to the field of computational biology and bioinformatics, particularly her discovery of human accelerated regions, and development of open-source software for gene expression, comparative genomics, and microbiomes."
  • "I'm honored to be named an AAAS Fellow, joining the ranks of some of the most noted scientists in history," Pollard says.
  • Pollard also is an elected member of the National Academy of Medicine and a fellow of the California Academy of Sciences, among many other honors and awards.

Announcing the 2024 John Simon Guggenheim Memorial Foundation Fellows

Retrieved on: 
Donnerstag, April 11, 2024
Climate change, Human, Guggenheim Fellowship, Head, Woman, Authoritarianism, Biography, Machine learning, Genetic variation, Game theory, Trustee, Data, Fellow, Culture, Choreography, DNA, Mathematics, Friends, Rank, Politics, Theory, Environmental studies, Geography, Democracy, Ageing, Wood, Imprisonment, Disability, Climate, Earth science, Nursing

NEW YORK , April 11, 2024 /PRNewswire-PRWeb/ -- The Board of Trustees of the John Simon Guggenheim Memorial Foundation announced today their appointment of 188 Guggenheim Fellowships to a distinguished and diverse group of culture-creators working across 52 disciplines. Chosen through a rigorous application and peer review process from a pool of almost 3,000 applicants, the Class of 2024 Guggenheim Fellows was tapped on the basis of prior career achievement and exceptional promise. As established in 1925 by founder Senator Simon Guggenheim, each fellow receives a monetary stipend to pursue independent work at the highest level under "the freest possible conditions."

Key Points: 
  • The John Simon Guggenheim Memorial Foundation Taps 188 Artists, Scholars, Photographers, Novelists, Essayists, Poets, Historians, Choreographers, Environmentalists, and Data Scientists to the Ranks of 19,000 Fellows Honored Since 1925 *** Now in 99th year, the John Simon Guggenheim Memorial Foundation recognizes & awards monetary prizes to the 2024 class of trail-blazing fellows across 52 fields
    NEW YORK , April 11, 2024 /PRNewswire-PRWeb/ -- The Board of Trustees of the John Simon Guggenheim Memorial Foundation announced today their appointment of 188 Guggenheim Fellowships to a distinguished and diverse group of culture-creators working across 52 disciplines.
  • - Edward Hirsch, president of the John Simon Guggenheim Memorial Foundation
    To see the full list of new Fellows, please visit www.gf.org .
  • "Humanity faces some profound existential challenges," said Edward Hirsch, award-winning poet and president of the John Simon Guggenheim Memorial Foundation.
  • Fellows in the creative arts are partially supported by the Joel Conarroe Fund, named for the former President of the Foundation who was a 1977 Guggenheim Fellow.

Dovetail Genomics Introduces Novel LinkPrep™ NGS Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Dienstag, April 9, 2024
Genetic variation, Gene, Genetics, Patient, NGS, 3D, Chromatin, Cancer, Genome, Workflow, Genomics, Poster, Chromosomal translocation, Mobile phone

BOSTON, April 9, 2024 /PRNewswire/ -- Dovetail Genomics today announces the debut of its LinkPrep™ NGS technology, showcasing its potential for de novo detection of structural variants and chromatin topology features in cancer. Through its innovative chromatin conformation approach, LinkPrep™ technology exhibits enhanced sensitivity in detecting translocations and intra-chromosomal rearrangements compared to conventional methods, while also identifying SNVs/InDels within a single assay. Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift. These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.

Key Points: 
  • Unlike traditional Hi-C methods, LinkPrep technology offers a streamlined process, generating sequenceable libraries from initial samples in a single shift.
  • These findings are being presented at the AACR Annual Meeting, April 5-10, in San Diego, Calif.
  • This will improve the discovery and annotation of novel drivers and mechanisms of cancer.
  • Currently undergoing late-stage validation, Dovetail Genomics is actively seeking strategic partnerships to conduct further studies demonstrating its clinical utility across specific cancer indications.

Twist Bioscience Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations

Retrieved on: 
Donnerstag, März 28, 2024
Research, Technology, Semiconductor, Genetics, Nanotechnology, Biotechnology, Hardware, Health, Data Management, Science, Genetic variation, Panel, NHGRI, Twist Bioscience, Twist, WES, Genome, Doctor of Philosophy, Sequence, Production, Exome, Silicon

In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • In order to advance science for all people, researchers need to have tools that enable them to conduct research relevant to people from diverse backgrounds,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • “When companies such as Twist utilize our reference standard to create research tools, it facilitates scientists’ study of genetic variation.
  • The Twist Human Pangenome Spike-in Panel targets 2.5 Mb of pangenome variants and can be spiked into the Twist Exome 2.0 to target more than 94% of the novel pangenome variants affecting coding sequences in the exome.
  • If interested in the Human Pangenome Spike-in Panel for the Twist Exome 2.0 panel, please complete the contact form here: https://www.twistbioscience.com/contact